This article shows how much of a decrease in cancer deaths there ARE
by keeping the iron levels lower.
"Overall, 75% of new cancers occurred in patients with mean ferritin
levels > 57 ng/mL."
"These results almost seem to be too good to be true."
Studies HAVE shown that hepatitis patients don't have liver cancer
ANYWHERE near those in the higher iron.
http://tinyurl.com/6chtoe
"None developed hepatocellular carcinoma (HCC)."
--------------
"These results almost seem to be too good to be true."
Reducing Iron Stores by Phlebotomy Lowers Cancer Risk in Older Men
NEW YORK (Reuters Health) Jul 08 - Cancer incidence and mortality in
older men may be reduced by repeated phlebotomy to lower serum
ferritin levels, according to findings published online on July 8 in
the Journal of the National Cancer Institute.
Observational studies suggest that lower body iron stores may protect
against malignancy by reducing iron-induced oxidative stress, Dr. Leo
R. Zacharski and his associates note.
To test this possibility, Dr. Zacharski, at the White River Junction
Veterans Affairs Medical Center, Vermont, and his group conducted an
ad hoc analysis of data from a VA study in which patients with
peripheral arterial disease were assigned to repeated blood
collections (n =3D 636) or to a control group (n =3D 641), originally for
prevention of atheroscl*****c complications .
The population was 99% male, mean age 67 years, with mean ferritin
levels at baseline of 122 ng/mL. Phlebotomy was scheduled every
6months to maintain ferritin levels between 25 and 60 ng/mL. During a
mean follow-up of 4.5 years, there were 60 new visceral malignancies
in the control patients and 38 in the iron-reduction patients (p =3D
0.023).
The risk of new malignancy (hazard ratio 0.65, p =3D 0.036) was
significantly lower in the phlebotomy group. Among patients who did
develop cancer, cancer-specific mortality (HR 0.39, p =3D 0.003) and
all- cause mortality (HR 0.49, p =3D 0.009) were lower in the phlebotomy
group.
Overall, 75% of new cancers occurred in patients with mean ferritin
levels > 57 ng/mL.
These findings do not pertain to younger patients without vascular
disease, women, or African Americans, whose ferritin levels are
higher than those of Caucasians, the investigators say. Instead,
"these observations provide incentive for future studies and insight
into optimal clinical trial design."
Dr. Zacharski's team suggests "there may be a need to redefine the
normal range for the serum ferritin level based on associated disease
risk." They also call for re-evaluation of the policy of routinely
administering iron to anemic cancer patients.
In a related editorial, Dr. Mads Melbye, at Statens Serum Institut in
Copenhagen and colleagues suggest that "these results almost seem to
be too good to be true."
While recommending that "all possibilities for bias must be carefully
examined" and that "the results have to be interpreted with caution,"
the editorialists also sup****t more research on this topic.
Furthermore, they write, "a cautious standpoint toward iron
supplementation where no proper indication exists is perhaps
advisable."
J Natl Cancer Inst 2008;100.
-----------------------------------
Decreased Cancer Risk After Iron Reduction in Patients With
Peripheral
Arterial Disease: Results From a Randomized Trial.
Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL,
Malenka DJ, Ozaki CK, Lavori PW
J Natl Cancer Inst 2008 Jul 8.
Background
Excess iron has been implicated in cancer risk through increased
iron- catalyzed free radical-mediated oxidative stress.
Methods
A multicenter randomized, controlled, single-blinded clinical trial
(VA Cooperative Study #410) tested the hypothesis that reducing iron
stores by phlebotomy would influence vascular outcomes in patients
with peripheral arterial disease.
Patients without a visceral malignancy in the last 5 years (n =3D 1277)
were randomly assigned to control (n =3D 641) or iron reduction (n =3D
636).
Occurrence of new visceral malignancy and cause-specific mortality
data were collected prospectively.
Cancer and mortality outcomes in the two arms were compared using
intent-to-treat analysis with a Cox pro****tional hazards regression
model.
Statistical tests were two-sided.
Results
Patients were followed up for an average of 4.5 years.
Ferritin levels were similar in both groups at baseline but were
lower in iron reduction patients than control patients across all 6-
month visits (mean =3D 79.7 ng/mL, 95% confidence interval [CI] =3D 73.8
to 85.5 ng/mL vs 122.5 ng/mL, 95% CI =3D 115.5 to 129.5 ng/mL; P < .
001).
Risk of new visceral malignancy was lower in the iron reduction group
than in the control group (38 vs 60, hazard ratio [HR] =3D 0.65, 95% CI
=3D 0.43 to 0.97; P =3D .036), and, among patients with new cancers, those
in the iron reduction group had lower cancer-specific and all-cause
mortality (HR =3D 0.39, 95% CI =3D 0.21 to 0.72; P =3D .003; and HR =3D
0.4=
9,
95% CI =3D 0.29 to 0.83; P =3D .009, respectively) than those in the
control group.
Mean ferritin levels across all 6-monthly visits were similar in
patients in the iron reduction and control groups who developed
cancer but were lower among all patients who did not develop cancer
than among those who did (76.4 ng/mL, 95% CI =3D 71.4 to 81.4 ng/mL, vs
127.1 ng/mL, 95% CI =3D 71.2 to 183.0 ng/mL; P =3D .017).
Conclusions
Iron reduction was associated with lower cancer risk and mortality.
Further studies are needed to define the role of body iron in cancer
risk.
Journal of the National Cancer Institute [J Natl Cancer Inst]
---------------------------------------------------------------------------=
=AD=AD-----
Jerome Sullivan, M.D. (working in the U.S. Veterans Administration)
recognized about 20 years ago that people with (iron- deficiency)
anemia had almost no atherosclerosis.
http://www.mum.org/stopmen3.htm
----------------
Who loves ya.
Tom
Jesus Was A Vegetarian!
http://tinyurl.com/2r2nkh
Man Is A Herbivore!
http://tinyurl.com/4rq595
DEAD PEOPLE WALKING
http://tinyurl.com/zk9fk
|
